
Company Introduction
Belief BioMed Group (BBM) was founded in September 2016, is a leading innovative pharmaceutical company that combines gene therapy drug R&D, manufacturing platforms and clinical transformation. The Company established offices,R&D centers and manufacturing in China Shanghai, Beijing, Suzhou, Hong Kong and North Carolina. BBM is committed to providing innovative therapies for single gene disorder diseases, neurodegenerative diseases and malignant diseases through adeno-associated virus (AAV) vector technology.
BBM has its own patents for a variety of AAV vectors, as well as dozens of new capsids with extremely specific tissue tropism. BBM invented recombinant AAV packaging technology has been widely used in the field of AAV gene therapy. BBM has extremely rich pipelines, that covering a variety of major and unmet clinical needs such as hemophilia, Parkinson's disease, Lysosomal storage disease, Hereditary neuromuscular disease, Hereditary muscle diseases, Ophthalmology disease and so on. Several pipelines launched the investigator initiated clinical trial and entered Investigational New Drug (IND) application stage. The available clinical data showed that the drugs had significant safety and efficacy. BBM successfully developed the world's leading serum-free suspension culture process based on HEK 293 cells (200L and 500L processes have been successfully put into production) and the large-scale purification process based on chromatography.
On August 6th, 2021, China’s National Medical Products Administration (NMPA) has cleared the IND (Investigational New Drug) application for Belief BioMed’s BBM-H901 using prophylactic treatment of hemophilia B in adult male. This is the first IND approval for AAV gene therapy for Hemophilia in China, and the first intravenous infusion gene therapy for rare diseases in China.
Mission And Vision

Our Mission
Make gene therapy drugs available, affordable and healable.

Our Vision
To become the pioneer leading China’s gene therapy industry, to bring China’s gene therapy drugs to the world.
Key Milestones
Management Team

Xiao Xiao
Co-Founder, Chairman and CSO, Ph.D.
Ph.D. in Molecular Biology, University of Pittsburgh
Co-founder of Bamboo / Askbio

Jane Zheng
Co-founder and CEO, Ph.D.
PhD from Institute of Neurology, Chinese Academy of Sciences
Co-founder of Genechem / Neuron Biotech

Hao Zheng
Operations Senior VP
Tianjin university Pharmaceutical engineering, Bachelor
15 years of experience in pharmaceutical operation management

Yuntao Gong
Medical VP
Peking University, Neuroscience, Ph.D.
15 years of experience in Clinical Development/Medical Affairs

Hui Chen
Portfolio Regulatory, VP
Fudan University, Master
19 years of experience in pharmaceutical R&D

Xia Wu
Pipeline R&D, VP
Utah State University, Postdoc.
15 years of experience in AAV early discovery

Wei Jiang
Analytical Development, Senior Director
Institute of Biochemistry, CAS, Ph.D.
8 years of experience in AAV vector application

Philip Sin
SVP
Corporate Funding and Development Department
Dartmouth College , Economics Bachelor
Senior financial services executive with 20 years of experience

Zengmin Du
Process R&D, Senior Director
East China University of Science and Technology, Ph.D.
8 years of experience in AAV vector R&D

Yue Dun
Clinical Vice President
Peking University, Master
15 years of experience in clinical development